News Search Results
Mar 04, 2025, 20:23 ET Avecho и Sandoz заключили эксклюзивное соглашение о лицензировании и разработке с целью коммерциализации КБД для лечения бессонницы в Австралии
МЕЛЬБУРН, Австралия, 4 марта 2025 г. /PRNewswire/ -- Сегодня компания Avecho Biotechnology Limited (ASX: AVE) («Avecho» или «Компания») объявила о подписании эксклюзивного десятилетнего соглашения о разработке и лицензировании с Sandoz
More news about: Avecho Biotechnology
Mar 04, 2025, 16:54 ET AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Mar 04, 2025, 16:01 ET Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and full year ended December
More news about: Rigel Pharmaceuticals, Inc.
Mar 04, 2025, 14:46 ET Stream Biomedical, Inc. Announces Acceptance of Abstract for Presentation at Annual Meeting of the American Society of Neurotherapeutics (ASENT) Conference 2025
March 4, 2025 /PRNewswire/ -- Stream Biomedical, Inc. ("Stream"), a clinical-stage biotechnology company developing novel solutions for acute and chronic neurodegenerative diseases, today announced acceptance of an abstract for presentation
More news about: Stream Biomedical, Inc.
Mar 04, 2025, 13:47 ET Avecho a Sandoz uzavírají exkluzivní smlouvu o licencování a vývoji CBD pro léčbu nespavosti v Austrálii
MELBOURNE, Austrálie, 4. března 2025 /PRNewswire/ -- Společnost Avecho Biotechnology Limited (ASX: AVE) („Avecho" nebo „společnost") dnes oznámila, že se společností Sandoz Group AG („Sandoz") podepsala exkluzivní desetiletou smlouvu
More news about: Avecho Biotechnology
Mar 04, 2025, 13:45 ET Avecho a Sandoz uzatvárajú exkluzívnu licenčnú dohodu a dohodu o vývoji na komercializáciu CBD na nespavosť v Austrálii
MELBOURNE, Austrália, 4. marca 2025 /PRNewswire/ -- Avecho Biotechnology Limited (ASX: AVE) (ďalej len „Avecho" alebo „spoločnosť") dnes oznámila, že podpísala exkluzívnu desaťročnú dohodu o vývoji a licenčnú dohodu so
More news about: Avecho Biotechnology
Mar 04, 2025, 13:42 ET Mesotherapy Market Size Expected to Reach US$ 1,148.60 Million by 2030, Growing at a 9.4% CAGR, According to The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Mar 04, 2025, 13:14 ET Hyperpigmentation Disorder Treatment Market Size to Reach US$ 11.78Billion by 2030, Growing at 7.4% CAGR, Says The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Mar 04, 2025, 12:12 ET Magnet Biomedicine Selects Simplicis's Ledger™ Platform to Lead Innovation in Compound Management
BOSTON, March 4, 2025 /PRNewswire/ -- Magnet Biomedicine, a biotechnology company advancing molecular glue discovery through rational selection and design, has selected Simplicis's Ledger™ platform after a rigorous evaluation
More news about: Simplicis
Mar 04, 2025, 11:29 ET Avecho et Sandoz concluent un accord exclusif de licence et de développement pour commercialiser le CBD contre l'insomnie en Australie
MELBOURNE, Australie, 4 mars 2025 /PRNewswire/ -- Avecho Biotechnology Limited (ASX : AVE) (« Avecho » ou la « Société ») a annoncé aujourd'hui la signature d'un accord exclusif de développement et de licence portant
More news about: Avecho Biotechnology
Mar 04, 2025, 11:27 ET Avecho y Sandoz firman un acuerdo exclusivo de licencia y desarrollo
MELBOURNE, Australia, 4 de marzo de 2025 /PRNewswire/ -- Avecho Biotechnology Limited (ASX: AVE) ("Avecho" o la "Compañía") anunció hoy que ha firmado un acuerdo exclusivo de desarrollo y licencia por diez años con Sandoz
More news about: Avecho Biotechnology
Mar 04, 2025, 10:45 ET Medical Refrigerators Market Size Set for Tremendous Growth, Projected to Reach US$ 6.49 Billion by 2028, Growing at 5.8% CAGR, Says The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Mar 04, 2025, 10:30 ET Antimicrobial Coating Market Size to Reach US$ 8.82 Billion by 2031 Owing to Increasing Demand for Hygiene and Infection Control | Exclusive Report by The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Mar 04, 2025, 10:00 ET Solarea Bio to Showcase Innovations at 2025 Future Food-Tech Summit
Solarea Bio, a clinical-stage biotechnology company unlocking the power of the edible plant microbiota to improve human health, is showcasing its innovative natural solutions for some inflammatory-related
More news about: Solarea Bio
Mar 04, 2025, 09:51 ET Data and Safety Monitoring Board Approves LyGenesis's Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration
LyGenesis, Inc., a clinical-stage biotechnology company developing cell therapies for organ regeneration, today announced that the Data and Safety Monitoring Board (DSMB) has completed its review
More news about: LyGenesis, Inc.
Mar 04, 2025, 09:00 ET Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials
organization. From molecule to medicine, we advance clinical research providing outsourced development and commercialization services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient
More news about: Mural Health
Mar 04, 2025, 08:09 ET Robles BioCeutics Appoints Chief Financial Officer
Cell Senolytics Biotechnology Company SAN DIEGO, March 4, 2025 /PRNewswire/ -- Robles BioCeutics, a regenerative dermatology biotechnology company focused
More news about: Robles BioCeutics
Mar 04, 2025, 08:03 ET Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the last patient has completed their
More news about: Dermata Therapeutics, Inc.
Mar 04, 2025, 07:31 ET REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
Track designations from the U.S. Food and Drug Administration. ABOUT REGENXBIO Inc.REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development
More news about: REGENXBIO Inc.
Mar 04, 2025, 05:45 ET Lost Money on ICON Public Limited Company(ICLR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Mar 03, 2025, 23:28 ET Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®
biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Mar 03, 2025, 19:27 ET Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
MELBOURNE, Australia, March 3, 2025 /PRNewswire/ -- Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company") today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz
More news about: Avecho Biotechnology
Mar 03, 2025, 17:31 ET Global In Situ Hybridization Market to Grow at a CAGR of ~7% by 2032 | DelveInsight
novel ISH reagents and diagnostic kits. Strategic collaborations, acquisitions, and partnerships with academic institutions, hospitals, and biotechnology firms are common strategies employed by these companies to expand their product portfolios and access new markets. Additionally, regional market
More news about: DelveInsight Business Research, LLP
Mar 03, 2025, 17:00 ET Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
MELBOURNE, Australia, March 3, 2025 /PRNewswire/ -- Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company") today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz
More news about: Avecho Biotechnology
Mar 03, 2025, 11:52 ET Parenteral Nutrition Market Size to Hit $11.12 Billion, Globally, by 2030 | Exclusive Report by The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Related
More news about: The Insight Partners